Liver transplantation

Current Opinion in Gastroenterology

Volumn 20, Issue 3, 2004, Pages 264-269

  Brown, Kimberly A ^a   Moonka, Dilip ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Hepatitis B; Hepatitis C; Liver; MELD; Organ donation

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B ANTIBODY; INTERFERON; LAMIVUDINE; RIBAVIRIN;

AGE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETES MELLITUS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; LIVER DISEASE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; ORGAN DONOR; RACE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; VIRUS HEPATITIS; VIRUS RESISTANCE;

EID: 1942421144     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200405000-00011     Document Type: Review

References (41)

1. 1 www.unos.org
2. Weisner R, Edwards E, Freeman R, et al.: and The United Network For Organ Sharing Liver Disease Severity Score Committee. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91-96. A prospective study of 3437 patients evaluating the ability of the MELD score to correctly rank patients with chronic liver disease according to their risk of death on the OPTN waiting list.
3. Botta F, Giannini E, Romagnoli P, et al.: MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. Gut 2003, 52:134-139.
4. Merion RM, Wolfe RA, Dykstra DM, et al.: Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003, 9:12-18. An intriguing study suggesting that the change in MELD score over time is more predictive of death on the waiting list than the listing MELD score.
5. Onaca NN, Levy MF, Sanchez EQ, et al.: A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003, 9:117-123. The authors evaluate the correlation between the MELD score at transplantation and mortality up to 2 years after transplant.
6. Saab S, Wang V, Ibrahim AB, et al.: MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003, 9:473-476.
7. Hayashi PH, Forman L, Steinberg T, et al.: Model for end-stage liver disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl 2003, 9:737-740.
8. Ellison MD, Edwards LB, Edwards EB, et al.: Geographic differences in access to transplantation in the United States. Transplantation 2003, 76:1389-1394. A study looking at differences in access to transplant in the United States, suggesting that despite recent changes in allocation of livers, significant regional variations in access remain.
9. Schaffer RL, Kulkarni S, Harper A, et al.: The sickest first? Disparities with model for end-stage liver disease-based organ allocation: One region's experience. Liver Transpl 2003, 9:1211-1215.
10. Biggins SW, Beldecos A, Rabkin JM, et al.: Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002, 8:313-322.
11. Rosen HR, Madden JP, Martin P: A model to predict survival following hepatic retransplantation. Hepatology 1999, 6:365-370.
12. Rosen HR, Prieto M, Casanovas-Taltavull T, et al.: Validation and refinement of survival models for liver retransplantation. Hepatology 2003, 38:460-469. An excellent study looking at models to predict survival after retransplantation of the liver.
13. http://organdonation.iqsolutions.com
14. Brown RS, Russo MW, Lai M, et al.: A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003, 348:818-825. The most complete collection of data to present on practice in the United States regarding adult living donor liver transplantation.
15. Malago M, Testa G, Frilling A, et al.: Right living donor liver transplantation: An option for adult patients: single institution experience with 74 patients. Ann Surg 2003, 238:853-863.
16. Lewis MB, Howdle PD: Neurologic complications of liver transplantation in adults. Neurology 2003, 61:1174-1178. An excellent review of the authors' experience with the range of neurologic sequelae after liver transplantation.
17. Kanwal F, Chen D, Ting L, et al.: A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl 2003, 9:1312-1319.
18. Lewis MB, Howdle PD: Cognitive dysfunction and health-related quality of life in long-term liver transplant survivors. Liver Transpl 2003, 9:1145-1148.
19. O'Carroll RE, Couston M, Cossar J, et al.: Psychological outcome and quality of life following liver transplantation: A prospective, national, single-center study. Liver Transpl 2003, 9:712-720.
20. Karam V, Castaing D, Danet C, et al.: Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. Liver Transpl 2003, 9:703-711.
21. Bucuvalas JC, Britto M, Krug S, et al.: Health-related quality of life in pediatric liver transplant recipients: A single-center study. Liver Transpl 2003, 9:62-71.
22. Ojo AO, Held PJ, Port FK, et al.: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940. An important study of the cumulative incidence of chronic renal failure in 69,321 recipients of non renal transplants. The factors correlating with risk of chronic renal failure are explored.
23. Nair S, Eason J, Loss G: Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003, 9:126-129.
24. Fairbanks KD, Eustace JA, Fine D, et al.: Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003, 9:1079-1085.
25. Dunkelberg JC, Trotter JF, Wachs M, et al.: Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003, 9:463-468.
26. Perrillo R, Wright T, Rakela J, et al.: A multicenter United States-Canadian trial of lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33:424-432.
27. Han SH, Martin P, Edelstein M, et al.: Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003, 9:182-187.
28. Bienzle U, Gunther M, Neuhaus R: Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811-819.
29. Schiff ER, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003, 38:1419-1427. An important report on the efficacy of adefovir dipivoxil in patients with lamivudine-resistant HBV after liver transplant.
30. Nery JR, Nery-Avila C, Reddy KR: Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003, 75:1179-1186.
31. de Villa VH, Chen YS, Chen CL: Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation 2003, 75(3 Suppl):S49-53.
32. Hwang S, Moon DB, Lee SG, et al.: Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantation. Transplantation 2003, 75(3Suppl):S45-48.
33. Lo CM, Fan ST, Liu CL, et al.: Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003, 9:827-832.
34. Charlton M: The impact of advancing donor age on histologic recurrence of hepatitis C infection: the perils of ignored maternal advice. Liver Transpl 2003, 9:535-537.
35. Watt KDS, Lyden ER, McCashland TM: Poor survival after liver retransplantation: is hepatitis C to blame. Liver Transpl 2003, 9:1019-1024. An important study that utilizes the UNOS database to look at survival after retransplantation for recurrent HCV.
36. Neuberger J: Treatment of hepatitis C virus infection in the allograft. Liver Transpl 2003, 9:S101-S108.
37. Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
38. Mukherjee S, Gilroy RK, Rogge J, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis for recurrent hepatitis C in liver transplantation - a single center experience. Hepatology 2003, 38(suppl 1):227A.
39. Saab S, Hu R, Ibrahim AB, et al.: Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. Am J Transplant 2003, 3:328-333.
40. Ghobrial RM, Amersi F, Farmer DG, et al.: Baquerizo. Rapid and severe early HCV recurrence following adult living donor liver transplantation. Am J Transplant 2002, 2:163A.
41. Gaglio PJ, Malireddy S, Levin BS, et al.: Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003, 9:1028-1035.